Slide A Vision for a
Life Sciences & Biotechnology Strategy
READ MORE EUROPABIO MANIFESTO Unleashing the full potential of Life Sciences and Biotechnology in Europe
February 24, 2021

European Health Emergency Preparedness and Response Authority (HERA) Consultation – EuropaBio’s Feedback

February 15, 2021

The Business of Biotechnology: Growing for Europe’s tomorrow

February 12, 2021

EuropaBio and Alexion: RARE Conversations (Take Two) Keeping Rare Disease Patients In The Centre Of Discussion

February 12, 2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

February 2, 2021

Measuring the economic footprint of the Biotechnology Industry in Europe (WifOR Study)

January 29, 2021

Building a European Health Union

January 28, 2021

European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation

January 20, 2021

Revision of the EU legislation on medicines for children and rare diseases

November 30, 2020

Call for more effective EU regulation of Clinical Trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

November 25, 2020

EuropaBio Statement on the EU Pharmaceutical Strategy

November 2, 2020

EuropaBio announces Dr. Claire Skentelbery as new Director General of the Association

October 20, 2020

EU ATMP Hospital Exemption

October 20, 2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

October 19, 2020

Application of the ATMP Hospital Exemption in the EU

October 2, 2020

#EFIB2020 goes digital – EuropaBio hosts 13th annual European Industrial Biotechnology and Bioeconomy Conference

September 30, 2020

EuropaBio Patient engagement with the European Medicines Agency

September 3, 2020

Novartis’s Andrew Topen appointed as new Chairman of EuropaBio

August 13, 2020

Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations

August 3, 2020

Joint Statement on the Health Innovation Partnership Proposal

July 30, 2020

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

July 30, 2020

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

July 30, 2020

EuropaBio response to the Work Programme of the eHealth Stakeholder Group

July 15, 2020

EuropaBio position paper on the Farm to Fork Strategy

June 30, 2020

EuropaBio observations in response to Europe’s Beating Cancer Plan

 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe

FOLLOW US HERE


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


facebook
twitter
instagram
linkedin
youtube
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
February 20, 2019

Export Manufacturing Waiver for Supplementary Protection Certificates: a red flag for investment in EU healthcare biotech

As the Association representing the European biotechnology industry, EuropaBio is fully committed to the development of a legislative environment which facilitates the creation of EU jobs and growth as well as new solutions to healthcare challenges.
November 29, 2017

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
June 6, 2017

EuropaBio launches recommendations to enhance transparency of biosimilar labels

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
May 27, 2017

Biosimilar SmPC Recommendations

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
January 23, 2017

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

European Commission Initiative Improves Information for Patients on Biosimilar Medicines.
Become a member